Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Curis logo — Working relentlessly to develop innovative and differentiate...

Curis

Working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients.

Founded 2000 United States Lexington, United States 133 employees Post-IPO Equity Biotechnology, Health Care

General Information

Company Name Curis
Founded Year 2000
Location United States Lexington, United States
Employees 133
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Curis. To contact Curis, visit curis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Curis

Curis, a publicly-traded biotechnology company (NASDAQ: CRIS), focuses on developing first-in-class and innovative therapeutics for cancer treatment. The company has three drug candidates in development: Emavusertib (CA-4948), CI-8993, and Fimepinostat. It also collaborates with Aurigene for immuno-oncology and precision oncology drug discovery. Curis holds exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and other significant molecules. Additionally, it collaborates with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc. on commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma. Founded in 2000, Curis recently received a Post-IPO Equity investment on 29 October 2024. The company is headquartered in the United States and seeks dedicated professionals who are passionate about making a difference in cancer patients' lives. For more information, visit Curis's website at www.curis.com.

Taxonomy: Oncology, Drug Development, Immunology, Clinical Development, Hematology, Therapeutics, Cancer Treatment, Small Molecule Inhibitors, Monoclonal Antibodies, Precision Oncology, Signal Pathway Drug Technologies, Collaborative Research, Publicly-Traded Company, Biomolecular Research

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
29 Oct 2024
Post IPO Equity Undisclosed -
06 Jul 2023
Post IPO Equity Undisclosed -
03 May 2018
Post IPO Equity Undisclosed -
30 Jul 2015
Post IPO Equity Undisclosed -
24 Feb 2015
Post IPO Equity Undisclosed -
23 Dec 2011
Post IPO Equity Undisclosed -
09 Nov 2011
Post IPO Equity Undisclosed -
12 Feb 2010
Post IPO Equity Undisclosed -
08 Jan 2001

Curis Alternatives & Competitors

Curis vs
Flare Therapeutics
Flare Therapeutics United States

Trailblazing the path to drugging transcription factors to discover precision medicines for cancer &...

Series B
62 employees
Biopharma, Biotechnology
Curis vs
Apollomics
Apollomics United States

We are a biopharmaceutical company committed to the discovery and development of mono- and combinati...

Post-IPO Equity
26 employees
Biotechnology, Health Care
Curis vs
Agennix
Agennix

Crafting novel therapies to enhance the length and quality of life for seriously ill patients worldw...

Venture round
Biopharma, Biotechnology

FAQ About Curis

Working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients.
Curis was founded in 2000.
Curis is headquartered in Lexington, United States.
Curis operates in Biotechnology and Health Care. Its work centres on Oncology, Drug Development, Immunology and Clinical Development.
Curis has approximately 133 employees.
Curis has completed 9 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Curis include Flare Therapeutics, Apollomics, Agennix, Redx Pharma, Pacylex Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Curis and Flare Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Curis, https://bouncewatch.com/company/curis, updated 6 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes